drugset / Trial / NCT03420469

Bupropion Stereoselective Disposition and CYP2D6-mediated Drug Interactions in Healthy Volunteers

NCT03420469

Non-randomizedSequentialOpen-labelBasic science

Summary

Primary objectives: 1. To comprehensively characterize steady state stereoselective pharmacokinetics of bupropion and its primary and secondary metabolites in healthy volunteers 2. To prospectively determine the time course (onset), extent and offset of CYP2D6 inhibition in relation to the pharmacokinetic profiles of bupropion and metabolites.

Timeline

Start
2018-06-05
Primary completion
2019-05-01
Completion
2019-05-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupropion Small molecule 150 mg Oral